What's Going On With Regeneron Pharmaceuticals Stock On Friday?
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Also Read: Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs.On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
再生元制药公司（NASDAQ:REGN）周五宣布，欧洲药品管理局人用药品委员会已经采纳积极意见，建议有条件批准odronextamab用于复发/难治性滤泡性淋巴瘤（FL）或复发/难治性弥漫性B细胞淋巴瘤（DLBCL），该药物在经过两条或两条以上的全身疗法之后。
Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or doesn't respond to treatment (refractory). Similarly, R/R diffuse large B-cell lymphoma (DLBCL) occurs when DLBCL relapses or doesn't respond to therapy.
复发/难治性滤泡性淋巴瘤（FL）指FL在初步治疗后复发或不应对治疗。同样，复发/难治性弥漫性B细胞淋巴瘤（DLBCL）是指DLBCL复发或不应对疗法的情况。
The European Commission is expected to announce a final decision in the coming months.
欧盟委员会预计将在未来几个月宣布最终决定。
Also Read: Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs.
还阅读：高盛认为，再生元制药公司提高减重质量的方法是有价值的。
FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL).
FL和DLBCL是B细胞非何杰金淋巴瘤（B-NHL）的最常见亚型。
It is estimated that approximately 120,000 FL cases and 163,000 DLBCL cases are diagnosed annually worldwide. In Europe, it is estimated that approximately 15,000 FL cases and 31,000 DLBCL cases are diagnosed each year.
全球每年约有约120,000例FL和163,000例DLBCL病例被诊断出。在欧洲，每年约有约15,000例FL和31,000例DLBCL病例被诊断出。
The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab.
积极的CHMP意见得到了Phase 1 ELM-1和Phase 2 ELM-2试验的结果的支持，这些试验证明odronextamab具有持久的响应率和可接受的安全性。
Regeneron continues to evaluate the use of odronextamab as a monotherapy and in combination across earlier lines of therapy in challenging-to-treat lymphomas.
再生元制药公司继续评估odronextamab在治疗难以治疗的淋巴瘤早期线和组合疗法中的使用。
This includes the registrational ELM-1 and ELM-2 studies, the Phase 3 OLYMPIA development program, which is one of the largest clinical programs in lymphoma evaluating odronextamab in earlier lines of therapy and additional B-NHLs, and early-stage trials with chemotherapy-free combinations.
其中包括记录ELM-1和ELM-2研究、第三阶段OLYMPIA发展项目，该项目是评估odronextamab在早期治疗线和其他B-NHL中的最大临床项目之一，以及与无化疗的组合疗法的早期试验。
In addition to the Phase 3 OLYMPIA development program, Regeneron is investigating odronextamab in combination with a costimulatory bispecific antibody, REGN5837 (CD22xCD28), and Regeneron's cemiplimab for R/R aggressive B-NHL through the ATHENA-1 and CLIO-1 studies, respectively.
除了第三阶段OLYMPIA发展项目之外，再生元制药公司还通过ATHENA-1和CLIO-1研究调查odronextamab与一种共刺激双特异性抗体REGN5837（CD22xCD28）和再生元制药公司的CEMIPLIMAB联合用于R/R侵袭性B-NHL。
Price Action: REGN shares closed at $1,050.86 on Thursday.
REGN股票周四收盘价为1050.86美元。